by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
Two publications in JNNP explore the potential utility of therapies with differing mechanisms of action for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Querol et al evaluate the neonatal Fc receptor blocker rozanolixizumab, while...
by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
Driving a motor vehicle is an important skill set. Its evaluation is relevant to patients who had a stroke. These patients struggle to get back to driving because of physical deficits, including challenges from neglect and apraxia and the risk of unexpected future...
by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
One hundred and seventeen years after Alzheimer described the condition that bears his name, the first treatments have been identified which appear to modify its course.1 2 These treatments are monoclonal antibodies which clear one of the presumed pathogenic proteins...
by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
Background Hearing loss has been proposed as a modifiable risk factor for dementia. However, the relationship between hearing, neurodegeneration, and cognitive change, and the extent to which pathological processes such as Alzheimer’s disease and cerebrovascular...
by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
Background Blood neurofilament light chain (NfL) is increasingly considered as a key trial biomarker in genetic frontotemporal dementia (gFTD). We aimed to facilitate the use of NfL in gFTD multicentre trials by testing its (1) reliability across labs; (2) reliability...
